Lite Strategy (LITS) Registration Filing summary

Company overview and business model

• Operates as a pharmaceutical company with a portfolio of drug candidates, including voruciclib, an oral CDK9 inhibitor.

• Recently adopted a Litecoin treasury strategy, intending to use proceeds to acquire Litecoin as a primary reserve asset.

• Believes this approach will diversify reserves, enhance capital efficiency, and align with emerging financial technologies.

Financial performance and metrics

• Qualifies as a "smaller reporting company" with less than $250 million in public float or less than $100 million in annual revenues and less than $700 million in public float.

• Common stock trades on Nasdaq under the symbol "MEIP"; closing price on August 25, 2025, was $5.00 per share.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of shares by selling stockholders.

• May receive up to $13.8 million in gross proceeds if all warrants are exercised; intends to use all such proceeds to purchase Litecoin.